Neoadjuvant Camrelizumab for Triple-Negative Breast Cancer
Mené sur 441 patientes atteintes d'un cancer du sein triple négatif de stade précoce ou localement avancé (âge médian : 48 ans ; durée médiane de suivi : 14,4 mois), cet essai randomisé multicentrique de phase III évalue l'efficacité, du point de vue du taux de réponse complète, d'un ajout de camrélizumab à une chimiothérapie néoadjuvante à base de nab-paclitaxel et de carboplatine
Breast cancer is the most frequently diagnosed cancer globally and the leading cause of cancer-related deaths among women. Approximately 15% of breast cancers are classified as triple-negative breast cancer (TNBC). TNBC is characterized by the absence of the estrogen receptor, the progesterone receptor, and the human epidermal growth factor receptor 2, but it is a heterogeneous disease with varying histopathological and molecular features. In general, TNBC is more aggressive than other types of breast cancer and often gives rise to metastases. Chemotherapy forms the basis of systemic treatment. The most effective agents include taxanes, anthracyclines, platinum salts, cyclophosphamide, and capecitabine.
JAMA 2023